Published on: Jun 05, 2016 at Fierce Biotech

Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug

By : Fierce Biotech

Investigators on the drug say that Ganymed’s IMAB362 “can significantly extend median survival when added to standard chemotherapy–13.2 months vs. 8.4 months–for patients with advanced gastric cancer.”

Read More
SHARE